Study Reference No. - C2D02146

Study Type Demographic Gender Age Location Compensation
Birch Allergy Allergy to birch tree pollen Males and Females 18 to 65 Mississauga, ON $7,760
Study Details

Study Purpose

The primary purpose of this study is to find out if DM-101PX is safe and can be tolerated by the study participants. The test drug DM-101PX is under development for immunotherapeutic treatment of birch pollen allergy. It will be tested in the Environmental Exposure Chamber (EEC) where you will be exposed to birch pollen in an amount which will be similar to what you would be exposed to on a high pollen day in the natural environment.

Study Duration

The study consists of 2 screening visits (medical and EEC screening), 10 treatment visits and an end-of-study visit.

Study Schedule

General Screening

Currently pre-screening. Multiple dates available. Contact recruitment.

Medical Screening

Starts 07-September

Study Visit(s)

TBD in September

Follow-Up Visit(s)


Other Notes

Bring Valid Photo ID.

Refer a Friend and you may be eligible to receive up to $100 per referral.